Viewing nowCombinationCelebica Tablet 10/40 Milligrams
Olmesartan Medoxomil 40mg · Amlodipine Besylate 13.888mg
Tablet · Prescription medication · Combination
Celltrion Pharmaceutical Co., Ltd.

MFDS item code 201505169 · Approved 2015.07.30 · Insurance code 693901780
Treatment of essential hypertension not controlled with monotherapy
This medication is used to effectively lower and control blood pressure in patients with essential hypertension whose blood pressure is not sufficiently controlled with monotherapy of amlodipine or olmesartan medoxomil. It helps manage hypertension, reduce the risk of cardiovascular complications, and improve overall health.
Take 1 tablet of this medicine once daily with water, with or without food. It is recommended, if possible, to take it at the same time each day (e.g., in the morning). It is recommended that the doses of the individual components (amlodipine or olmesartan medoxomil) be adjusted before starting this medicine; however, if blood pressure is not controlled with monotherapy with the individual components, switching directly to this medicine may be considered. The maximum dose of this medicine is 10/40 mg. The maximum blood pressure-lowering effect occurs within 2 weeks after administration; therefore, adjust the dose at intervals of 2 weeks or longer, taking the patient's blood pressure response into account. The recommended doses are as follows: - 5/20 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or olmesartan medoxomil 20 mg as monotherapy. - 10/20 mg: For patients whose blood pressure is not adequately controlled with olmesartan medoxomil 20 mg as monotherapy. - 5/40 mg: For patients whose blood pressure is not adequately controlled with 5/20 mg. - 10/40 mg: For patients whose blood pressure is not adequately controlled with 5/40 mg. ○ Patients with renal impairment: This medicine has not been studied in patients with renal impairment. However, in patients with mild or moderate renal impairment (creatine clearance 20-60mL/min), the maximum dose of olmesartan medoxomil is 20 mg once daily. Use of this medicine is not recommended in patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or in patients receiving dialysis. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. ○ Patients with reduced effective intravascular volume: In patients who may have reduced effective intravascular volume (e.g., patients receiving diuretics, especially those with renal impairment), it is recommended to initiate treatment at a low dose while closely monitoring their condition. ○ Patients with hepatic impairment: Use with caution in patients with mild or moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil in patients with moderate hepatic impairment is 10 mg once daily, and the maximum dose is 20 mg once daily. In patients with hepatic impairment who are already receiving other antihypertensive medicines and/or diuretics, blood pressure and renal function should be closely monitored. Do not administer this medicine to patients with severe hepatic impairment. (See section 2, “Patients in whom this medicine must not be administered,” under Precautions for Use.) ○ Older adults: In general, initiate treatment at a low dose. When adjusting the dose, consider the patient's renal or cardiac function and comorbidities. In older adults, blood pressure should be monitored closely and more frequently.
○ Children: The safety and efficacy in pediatric patients under 18 years of age have not been established.
This drug can cause serious harm or death to the fetus and newborn if taken during the second and third trimesters of pregnancy; if pregnancy is confirmed, intake should be discontinued immediately. Do not use this drug if allergic to its active ingredients or similar classes of medications, or if pregnant or breastfeeding; patients with severely impaired liver or heart function, those undergoing kidney dialysis, patients in shock, or those with certain heart valve diseases should also avoid using it. Patients with fluid or salt depletion may experience low blood pressure, so careful monitoring of their condition should occur at the beginning of treatment, and appropriate measures should be taken if blood pressure drops too low. Since rapid blood vessel dilation can cause hypotension, caution is required in patients with severe heart disease. Patients with heart failure should use this medication cautiously, and careful monitoring is also necessary for patients with impaired kidney function. As this drug is primarily metabolized in the liver, it must be used carefully in patients with reduced liver function. Side effects such as dizziness, headache, lowered blood pressure, swelling, indigestion, skin rash, etc., may occur during treatment, and any unusual symptoms should be discussed with a healthcare provider. This drug may interact with other medications, so patients must inform their healthcare provider of any current medications being taken, and especially avoid taking this drug with grapefruit juice. The use of this drug during pregnancy may pose risks to the fetus; pregnant women or those planning to become pregnant should not use this drug, and breastfeeding mothers should either discontinue the medication or stop breastfeeding. Safety and efficacy in patients under 18 years of age have not been established, hence it is not recommended. Elderly patients may have impaired kidney and liver function, so they should start at low doses and have their dosage adjusted carefully. In case of overdose, severe hypotension and vascular expansion may occur, requiring immediate medical attention, along with careful monitoring of blood pressure and heart function. This drug should be stored in a sealed container, away from moisture and heat, and out of reach of children, and it is advisable not to transfer it to another container.
Not everyone experiences these, and they can vary from person to person.
This drug should be stored in a sealed container to prevent exposure to air or moisture, and it should be kept at room temperature between 1 and 30 degrees Celsius to ensure safety. Storing it this way will maintain the drug's effectiveness and prevent degradation.
Brownish-red round film-coated tablet
28 tablets/Alu-Alu
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationOlmesartan Medoxomil 40mg · Amlodipine Besylate 13.888mg
Tablet · Prescription medication · Combination
Celltrion Pharmaceutical Co., Ltd.
CombinationOlmesartan Medoxomil 20mg · Amlodipine Besylate 6.944mg
Tablet · Prescription medication · Combination
Korea Daiichi Sankyo Co., Ltd.
CombinationOlmesartan Medoxomil 40mg · Amlodipine Besylate 6.944mg
Tablet · Prescription medication · Combination
Korea Daiichi Sankyo Co., Ltd.
CombinationOlmesartan Medoxomil 40mg · Amlodipine Besylate 13.888mg
Tablet · Prescription medication · Combination
Hanmi Daiichi Sankyo Co., Ltd.
Olmesartan Medoxomil · Amlodipine Besylate
Prescription medication · Combination
SYNEX Co., Ltd.
Olmesartan Medoxomil · Amlodipine Besylate
Prescription medication · Combination
Co., Ltd. Sainex
Olmesartan Medoxomil · Amlodipine Besylate
Prescription medication · Combination
SYNEX Co., Ltd.
CombinationAmlodipine Besylate 6.944mg · Olmesartan Medoxomil 40mg
Tablet · Prescription medication · Combination
Huons Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.